ASCO Annual Meeting: Prostate Cancer | Conference

Extended ARAMIS Trial Follow-Up Shows Prolonged Tolerability of Darolutamide in nmCRPC
June 11, 2021

Almost all patients with nonmetastatic castration-resistant prostate cancer treated on the phase 3 ARAMIS trial were able to receive the full planned dose of darolutamide for their disease.

Lower Likelihood of Genomic Profiling Observed for Men With African Ancestry
June 08, 2021

Disparities regarding comprehensive genomic profiling came to light during a presentation at the 2021 ASCO Annual Meeting.

VISION Trail Results Indicate Benefit of 177Lu-PSMA-617A Added to Standard Therapy
June 03, 2021

A 40% reduction in the risk of death was observed when 177Lu-PSMA-617A was added to standard of care therapy in patients with PSMA-positive metastatic castration-resistant prostate cancer.